PDGFRa (G680R)
Sign in to save this workspacePDGFRA · Variant type: point · HGVS: p.G680R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Sorafenib | 96.5% | 3.5% | 96.72 |
| 2 | Tivozanib | 95.0% | 5.0% | 92.42 |
| 3 | Ripretinib | 87.1% | 12.9% | 92.95 |
| 4 | Avapritinib | 75.4% | 24.6% | 97.73 |
| 5 | Apatinib | 68.5% | 31.5% | 97.73 |
| 6 | Sunitinib | 63.1% | 36.9% | 91.73 |
| 7 | Selpercatinib | 48.3% | 51.7% | 96.72 |
| 8 | Erdafitinib | 43.5% | 56.5% | 95.71 |
| 9 | Quizartinib | 34.6% | 65.4% | 99.50 |
| 10 | Pexidartinib | 29.8% | 70.2% | 99.49 |
| 11 | Pralsetinib | 26.0% | 74.0% | 93.43 |
| 12 | Defactinib | 21.2% | 78.8% | 92.68 |
| 13 | Umbralisib | 20.4% | 79.6% | 98.74 |
| 14 | Fedratinib | 18.1% | 81.9% | 96.21 |
| 15 | Infigratinib | 17.8% | 82.2% | 98.24 |
| 16 | Paxalisib | 16.2% | 83.8% | 99.75 |
| 17 | Tenalisib | 13.1% | 86.9% | 97.98 |
| 18 | Gedatolisib | 12.4% | 87.6% | 99.75 |
| 19 | Upadacitinib | 11.9% | 88.1% | 97.98 |
| 20 | Rabusertib | 10.8% | 89.2% | 98.74 |
| 21 | Repotrectinib | 10.3% | 89.7% | 84.21 |
| 22 | Neratinib | 10.2% | 89.8% | 93.18 |
| 23 | Pirtobrutinib | 9.9% | 90.1% | 99.49 |
| 24 | Leniolisib | 9.0% | 91.0% | 100.00 |
| 25 | Lazertinib | 8.6% | 91.4% | 97.47 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Sorafenib | 96.5% | 95.6% | +0.9% |
| Tivozanib | 95.0% | 96.9% | -1.9% |
| Ripretinib | 87.1% | 81.5% | +5.6% |
| Avapritinib | 75.4% | 99.1% | -23.7% |
| Apatinib | 68.5% | — | — |
| Sunitinib | 63.1% | 84.2% | -21.0% |
| Selpercatinib | 48.3% | — | — |
| Erdafitinib | 43.5% | 94.5% | -51.1% |
| Quizartinib | 34.6% | — | — |
| Pexidartinib | 29.8% | — | — |
| Pralsetinib | 26.0% | — | — |
| Defactinib | 21.2% | — | — |
| Umbralisib | 20.4% | — | — |
| Fedratinib | 18.1% | — | — |
| Infigratinib | 17.8% | — | — |
| Paxalisib | 16.2% | — | — |
| Tenalisib | 13.1% | — | — |
| Gedatolisib | 12.4% | — | — |
| Upadacitinib | 11.9% | — | — |
| Rabusertib | 10.8% | — | — |
| Repotrectinib | 10.3% | — | — |
| Neratinib | 10.2% | — | — |
| Pirtobrutinib | 9.9% | — | — |
| Leniolisib | 9.0% | — | — |
| Lazertinib | 8.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| gastrointestinal_stromal_tumour_soft_tissue | Soft Tissue | ref |
| AML-US | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms